
The improved process allows researchers to use an advanced imaging method to study and analyze individual organoids in great detail.
Image Credit: Soragni Lab.
Scientific Frontline: Extended "At a Glance" Summary: AI-Powered High-Throughput Organoid Screening
The Core Concept: A novel drug-screening platform that integrates 3D bioprinting, advanced imaging, and artificial intelligence to evaluate the efficacy of cancer therapeutics on patient-derived tumor organoids in real time.
Key Distinction/Mechanism: Traditional systems measure average drug responses across a broad cell population. In contrast, this platform continuously tracks the growth dynamics and biomass changes of individual organoids without relying on destructive dyes or assays, utilizing AI to quantify distinct drug responses at a single-organoid resolution.
Major Frameworks/Components:
- Extrusion Bioprinting: Used to fabricate three-dimensional tumor organoids embedded within extracellular matrix constructs, specifically designed for high-throughput multiwell testing.
- Quantitative Phase Imaging: A high-speed, label-free imaging method that continuously monitors organoid biomass and growth dynamics to measure cellular fitness over time.
- Machine Learning and Deep Learning: Automated image reconstruction and segmentation algorithms process massive datasets to track individual organoid behaviors, identifying distinct therapeutic responses and tumor heterogeneity.





.png)


